Literature DB >> 9723425

Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation.

M Glanemann1, J M Langrehr, R Raakow, O Guckelberger, R Lohmann, J Klupp, H Lobeck, H Schlag, H Keck, W O Bechstein, U Settmacher, P Neuhaus.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 9723425     DOI： 10.1016/s0041-1345(98)00572-7

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  3 in total

Review 1.  Single-agent immunosuppression after liver transplantation: what is possible?

Authors:  Maria L Raimondo; Andrew K Burroughs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.

Authors:  Luit Penninga; André Wettergren; Colin H Wilson; An-Wen Chan; Daniel A Steinbrüchel; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2014-06-05

3.  Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis.

Authors:  Lawrence Mj Best; Jeffrey Leung; Suzanne C Freeman; Alex J Sutton; Nicola J Cooper; Elisabeth Jane Milne; Maxine Cowlin; Anna Payne; Dana Walshaw; Douglas Thorburn; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Norman R Williams; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2020-01-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.